Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
A phase 2 trial of envafolimab, gemcitabine and cisplatin in gallbladder cancer and other biliary tract cancers, run by 3D Medicines (Sichuan) Co., Ltd., not yet recruiting.
Overview
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers is a phase 2, randomised interventional study registered as NCT04910386 by 3D Medicines (Sichuan) Co., Ltd., with a registry enrolment figure of 126 participants, started 2027-06-01 and due to reach its primary completion in 2029-06. Interventions recorded: Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin. Conditions listed: Biliary Tract Neoplasms. Gallbladder cancer is named in the registry entry: "2. Subjects must have a histopathological or cytological diagnosis of locally advanced or metastatic gallbladder cancer (GBC) or cholangiocarcinoma (CCA);". No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialGemcitabine-Cisplatin Plus Envafolimab in Resectable Biliary Tract Malignancies
Shares Envafolimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialEnvafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Shares Envafolimab, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types) and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialStudy of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialChemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Biliary tract cancer (all types), Gemcitabine and the tag gallbladder-deep-dive.